Case Study – OneVoice™

OneVoice

Company:

$10B+

Original Support:

Hub & Copay

Therapeutic Area:

Rare Disease

Launch with Momentum:

2020

Approval Date:

2017

Momentum Products:

OneVoice

Original State

Company received product approval in 2017, and by 2020 had expansive financial support in place, including a 3rd party HUB and Copay program

Opportunity

Elevate patient support to meet the needs and expectations of patients in the rare disease space and establish a competitive advantage as competitors continue to come to market

Momentum Approach

Supplement the HUB program with virtual Clinical Nurse Educators (CNEs) who support patients as their go-to resource from time of prescription through ongoing therapy management

Program Overview

Program objectives:

  • Support patients by delivering an exemplary experience, ensuring patients are motivated to start on therapy
  • Ensure patients have the confidence and knowledge to start on therapy
  • Provide ongoing support to patients on therapy to help achieve long-term success

Solution

Journey

12+ months, from OneVoice™ onboarding to initiation to ongoing therapy management, personalized through predictive analytics and dynamic patient journey

Enrollment

Initiated from the HUB, via API integration

Channels

Omni-channel, including telephony, live video, mail, email, and text

Performance

Engagement

98%

of patients have an intention to start

9.79

average days from receipt to dispense

(compared to 18-day average)

Satisfaction

5/5

patient satisfaction rating

95%

continuation rate post therapy limitation

Confidence and Knowledge

4.7/5

reported patient confidence

4.8/5

reported patient understanding

Impact

90%

self-reported adherence

OneVoice™ Program Design: Patient Journey

patient journey - OnceVoice™

Innovation in the OneVoice™ Patient Support Program

Predictive analytics to personalize journey and topics discussed

Check-in communication if dispense is not meeting the intended timeline

Distinct journey for new, restart, discontinue, and at-risk patients

Medication reminders to help patients overcome logistical barriers

Client Measured Impact on Patient Adherence

At 90 Days:

Patients in Momentum patient support program had an 82% persistency rate vs. 71% for non-Momentum program patients, a 15% lift.

At 180 Days:

Patients in Momentum patient support program had an 64% persistency rate vs. 59% for non-Momentum program patients, an 8% lift.